

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR UNITS OR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE STOCK EXCHANGES (AS DEFINED IN THE DRHP) IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA. (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS")



Park Hospital



Please scan this QR code to view the Notice

PARK MEDI WORLD LIMITED

Our Company was incorporated in New Delhi as 'Park Medi World Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 20, 2011, issued by the Registrar of Companies, Delhi and Haryana at New Delhi ("RoC"). Subsequently, our Company was converted to a public limited company and the name of our Company has been changed to 'Park Medi World Limited' pursuant to a resolution passed by our Board on November 15, 2024 and by our Shareholders on November 18, 2024 and a fresh certificate of incorporation dated December 20, 2024 was issued by the Registrar of Companies, Central Processing Centre

Registered Office: 12, Meera Enclave Near Keshopur, Bus Depot, Outer Ring Road, New Delhi 110 018, Delhi
Corporate Office: Park Tower, Plot no. 521, Udyog Vihar Phase 3, Gurugram 122 022, Haryana
Contact Person: Abhishek Kapoor (Company Secretary and Compliance Officer)
Tel.: +91 124 696 0000 E-mail: company.secretary@parkhospital.in Website: www.parkhospital.in
Corporate Identity Number: U85110DL2011PLC212901

NAMES OF OUR PROMOTERS: DR. AJIT GUPTA AND DR. ANKIT GUPTA

NOTICE TO INVESTORS

In reference to the draft red herring prospectus dated March 28, 2025 ("DRHP"), filed by the Company with the Securities and Exchange Board of India ("SEBI"), BSE Limited and National Stock Exchange of India Limited ("Stock Exchanges") on March 29, 2025. Investors should note the following:

Our Company has received an intimation dated October 18, 2025 from Dr. Ajit Gupta, one of the Promoters of our Company and also our Promoter Selling Shareholder, that he has on October 18, 2025 transferred 6,172,840 Equity Shares (constituting 1.60% of our paid-up Equity Share Capital) having face value of ₹2 for cash at a price of ₹162.00 per Equity Share, aggregating up to approximately ₹1,000.00 million, pursuant to share purchase agreement dated October 17, 2025 executed between Dr. Ajit Gupta, Carnelian Bharat Amritkaal Fund, Carnelian Bharat Amritkaal Fund – 2, Carnelian Asset Management & Advisors Private Limited, and our Company ("Secondary Sale"). The details of the sale are:

Sr. No.	Date of transfer	Name of the transferor	Name of the transferee	Nature of relationship of transferor with the Company	Nature of transfer	Number of Equity Shares	Percentage of pre-Offer share capital of the Company	Transfer price per Equity Share (in ₹)	Total consideration (in ₹ million)
1	October 18, 2025	Dr. Ajit Gupta	Carnelian Bharat Amritkaal Fund	Promoter and Promoter Selling Shareholder	Secondary transfer	3,703,704	0.96	162.00	600.00
2	October 18, 2025	Dr. Ajit Gupta	Carnelian Bharat Amritkaal Fund – 2	Promoter and Promoter Selling Shareholder	Secondary transfer	925,926	0.24	162.00	150.00
3	October 18, 2025	Dr. Ajit Gupta	Carnelian Asset Management & Advisors Private Limited	Promoter and Promoter Selling Shareholder	Secondary transfer	1,543,210	0.40	162.00	250.00
Total						6,172,840	1.60%	-	1,000.00

Please note that Equity Shares transferred pursuant to the Secondary Sale do not form part of the Equity Shares proposed to be offered by our Promoter, as a part of minimum promoters' contribution. Further, please note that the Equity Shares transferred pursuant to the Secondary Sale, being the pre-Offer Equity share capital held by persons other than the Promoters shall be subject to lock-in, in accordance with Regulation 17 of the SEBI ICDR Regulations.

The aforementioned transferees, are not in any manner, connected with our Company, Promoter, Promoter Group, Directors, Key Managerial Personnel, Subsidiaries, and Group Companies and the directors and key managerial personnel of our Subsidiaries and Group Companies.

The pre and post Transfers shareholding of Dr. Ajit Gupta is as provided below:

Sr. No.	Name of the Shareholder	Pre-Transfer Shareholding		Post-Transfer Shareholding	
		Number of Equity Shares	Percentage of pre-Issue Equity Share capital (%)	Number of Equity Shares	Percentage of pre-Issue Equity Share capital (%)
1.	Dr. Ajit Gupta	345,322,485	89.83	339,149,645	88.23

Please note that this Notice does not purport to, nor does it, reflect all the changes that have occurred from the date of filing of the Draft Red Herring Prospectus and the date of this Notice. Accordingly, this Notice does not include all the changes and/or updates that will be included in the Red Herring Prospectus and the Prospectus. Please note that the information included in the Draft Red Herring Prospectus will be suitably updated, including to the extent updated byway of this Notice, as may be applicable, in the Red Herring Prospectus and the Prospectus. Investors should not rely on the Draft Red Herring Prospectus or this Notice for any investment decision, and should read the Red Herring Prospectus, as and when it is filed with the RoC, SEBI and the Stock Exchanges before making an investment decision with respect to the Offer.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER
	A CITIC Securities Company			
Nuvama Wealth Management Limited 801-804 Wing A Building No 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai 400 051, Maharashtra, India Tel: + 91 22 4009 4400 E-mail: parkhospitals ipo@nuvama.com Website: www.nuvama.com Investor Grievance ID: customerservice.mb@nuvama.com Contact Person: Pari Vaya SEBI Registration Number: INM000013004	CLSA India Private Limited 8/F Dalamal House, Nariman Point, Mumbai 400 021, Maharashtra, India Tel: + 91 22 6650 5050 E-mail: parkmediworld ipo@clsa.com Website: www.india.clsa.com Investor Grievance ID: investor.helpdesk@clsa.com Contact Person: Prachi Chandgothia/ Siddhant Thakur SEBI Registration Number: INM000010619	DAM Capital Advisors Limited Altimus 2202, level 22, Pandurang Budhkar Marg, Worli, Mumbai 400018 Tel: +91 22 4202 2500 E-mail: parkhospitals ipo@damcapital.in Website: www.damcapital.in Investor Grievance ID: complaint@damcapital.in Contact Person: Chandresh Sharma/Shital Shah SEBI Registration Number: MB/INM000011336	Intensive Fiscal Services Private Limited* 914, 9 th Floor, Raheja Chambers, Free Press Journal Marg, Nariman Point, Mumbai 400 021, Maharashtra, India Tel: +91 22 2287 0443 E-mail: park ipo@intensivefiscal.com Website: www.intensivefiscal.com Investor Grievance ID: grievance.ib@intensivefiscal.com Contact Person: Harish Khajanchi/Anand Rawal SEBI Registration Number: INM000011112	KFin Technologies Limited Selenium Tower B, Plot No. 31 and 32, Financial District, Nanakramguda, Serilingampally Hyderabad 500 032, Telangana, India Tel: +91 40 6716 2222 Website: www.kfintech.com E-mail: parkmedi ipo@kfintech.com Investor grievance e-mail: einward.ris@kfintech.com Contact Person: M. Murali Krishna SEBI Registration Number: INR000000221

*In accordance with the SEBI (Merchant Bankers) Regulations, 1992, read with Regulation 23(3) of the SEBI ICDR Regulations, Intensive Fiscal Services Private Limited has voluntarily undertaken to be associated only with the marketing of the Offer.

All capitalized terms used in this Notice shall, unless the context otherwise requires, have the same meaning as ascribed in the DRHP.

For **Park Medi World Limited**
On behalf of the Board of Directors
Sd/-
Abhishek Kapoor
Company Secretary and Compliance Officer

Place: New Delhi
Date: October 19, 2025

Park Medi World Limited is proposing, subject to, receipt of requisite approvals, market conditions and other considerations, to make an initial public issuance of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on March 29, 2025. The DRHP is available on the website of the Company at www.parkhospital.in, SEBI at www.sebi.gov.in, as well as on the websites of the BRLMs, i.e. Nuvama Wealth Management Limited, CLSA India Private Limited, DAM Capital Advisors Limited and Intensive Fiscal Services Private Limited at www.nuvama.com, www.india.clsa.com, www.damcapital.in and www.intensivefiscal.com, respectively and the websites of National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Potential investors should not rely on the DRHP for making any investment decision. Specific attention of the investors is invited to "**Risk Factors**" beginning on page 30 of the DRHP. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see "**Risk Factors**" of the RHP, when available.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("**U.S. Securities Act**"), or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in reliance on Regulation S and the applicable laws of the jurisdiction where those offers and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.